Paradigm Spine: Coflex Coding Advice and the Coflex-F Allegations

Whistleblower Justice Network

In the Paradigm Spine coflex settlement, the medical device manufacturer agreed to pay $585,000 to resolve allegations that it caused false claims through improper coding advice and promotion of coflex-F for unapproved surgical uses. The Justice Department identified the whistleblower who brought the case as a former Paradigm sales representative. His complaint reached into the conversations behind a spine implant sale: what the surgeon heard about the medical device, what the practice heard about getting paid, and what the company tracked internally about its use.

The Justice Department’s May 27, 2016 announcement described claims to Medicare and other federal health care programs. The government alleged that Paradigm’s instructions caused physicians and hospitals to bill for spine surgeries that were not eligible for reimbursement. The settlement held the manufacturer to account for its alleged role in claims submitted by providers.

What Providers Were Allegedly Told to Bill

Paradigm allegedly gave providers false recommendations for coding procedures involving coflex. The whistleblower’s complaint put a particular billing code at the center of that account and attributed a revealing description to a consultant:

MCRA admitted that using bill code 22840 would be “flying under the radar,” or, in other words, using 22840 would not be correctly and accurately describing the device.

Whistleblower’s allegation, United States ex rel. Coyle v. Paradigm Spine, LLC, complaint, paragraph 120

We see the absurdity in that alleged advice: the code was supposed to describe the procedure, yet the consultant allegedly discussed it as a way to escape attention. A sales pitch for the bill itself.

The complaint also alleged that a surgeon stopped using coflex because he disagreed with using that code. That detail matters to someone who sells medical devices or supports a practice’s reimbursement work. In the whistleblower’s account, the billing recommendation affected whether a surgeon would continue using the product. Coding advice belonged to the commercial relationship as well as the claim.

Coflex-F Promotion and Coflex Coding Advice

The government’s settlement announcement separated coflex-F promotion from coflex reimbursement guidance, with different periods for each. It alleged that Paradigm marketed coflex-F for surgical uses not approved by the Food and Drug Administration from 2011 to 2013. It separately alleged improper guidance on claiming reimbursement for coflex from 2012 to 2015.

The distinction gives an insider two different decisions to recognize. The first concerns what the manufacturer encouraged a surgeon to do with the medical device. The second concerns what the manufacturer told a provider to put on the bill. The government’s allegation connected both to physicians and hospitals submitting claims for surgeries that federal programs would not reimburse.

That is a familiar division of work in the implant business. The surgeon may choose or strongly influence the implant, while the hospital or surgery center purchases it. A manufacturer’s representative works close to that choice, supplying product knowledge and instrumentation. The resulting government-payment claim comes from the provider. Following the sale therefore means following the manufacturer’s influence through someone else’s clinical and billing decisions.

A Senate Finance Committee staff report describes representatives ordering, delivering, stocking and restocking instrumentation and assisting surgeons in the operating room. That proximity helps explain why a sales representative can know both what was promised and how the product was used. A coding recommendation delivered through that relationship deserves the same attention as the product pitch.

How Does Reimbursement Work for Medical Devices?

Medicare usually includes an implanted medical device’s cost in payment for the procedure or hospital stay. The hospital buys the implant, but the payment question follows the service in which it was used. That is why advice about the procedure’s billing code can matter so much to the manufacturer selling the medical device.

For a spine practice, a reimbursement recommendation can sound like the last practical answer needed before using a product. For the hospital, the implant’s purchase cost sits inside the economics of the procedure. In Paradigm’s case, the government challenged the manufacturer’s role in getting certain surgeries billed despite their alleged ineligibility for reimbursement. The focus was the provider’s claim and the advice that caused it.

What the Training Materials Allegedly Left Out

The whistleblower alleged that Paradigm withheld policy and coding material from the very documents used to market the product and train people to sell it. The complaint named the missing material:

Paradigm intentionally hid and omitted all of the above medical policies recommendations and determinations including the NASS T-code recommendation the Novitas and Cahaba coverage determinations and the AMA advisory instruction from its marketing, promotional and training materials

Whistleblower’s allegation, United States ex rel. Coyle v. Paradigm Spine, LLC, complaint, paragraph 113

The sales materials allegedly left out the guidance that cut against the pitch. The complaint identified coverage denials and contrary coding advice as information the company withheld. We see the problem plainly: a practice hearing the recommendation would be missing the reasons to question it.

For a sales or training insider, that is a concrete business decision. We would want to understand which materials reached representatives and providers, who decided what to include, and how the advice carried through to billing. The relationship between those documents is the point: what the company knew, what it told the customer, and what the customer then claimed.

What the Internal Coflex-F Tracker Allegedly Showed

The complaint alleged that Paradigm’s own tracking captured use of coflex-F at more than one spinal level. Its account gave the internal case tracker a different job from a sales brochure: recording what was happening in actual cases.

According to Paradigm’s internal Coflex-F case tracker, 40% of the cases in 2011 were more than one level (off-label) and more than 30% of the cases in 2012 were more than one level (off-label).

Whistleblower’s allegation, United States ex rel. Coyle v. Paradigm Spine, LLC, complaint, paragraph 169

Its allegation placed knowledge of multilevel use inside the company, in a tracker maintained by the business itself. The government’s settlement account, in turn, alleged promotion of unapproved surgical uses.

What Kind of Proof Is Needed to Be a Whistleblower?

In a medical device coding case, we work with you to connect the manufacturer’s recommendation to the provider’s procedure and claim, and to what the people giving the advice knew. Paradigm’s complaint makes that inquiry specific: coding advice, omitted policies, a surgeon’s objection and internal tracking of medical device use.

The 2020 Journal of Forensic and Investigative Accounting article A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud explains that the False Claims Act reaches someone who knowingly causes a false claim as well as someone who submits it. That distinction explains the manufacturer’s place in this case. The alleged influence began before the bill reached a federal healthcare program.

We examine how the recommendation moved through the business and into the practice. A training document explains what representatives were expected to say. A provider communication explains what the customer actually heard. A procedure record and claim show what was done and billed. An internal tracker can put the company’s knowledge beside those events. Each supplies a different part of the account, which is why someone inside sales or reimbursement may have a view the final bill cannot provide.

What the Paradigm Spine Settlement Resolved

The civil settlement resolved the former sales representative’s False Claims Act case over the two alleged routes to false provider claims. The Justice Department said the whistleblower would receive a share of the recovery.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

Another Medical Device Sold With Advice About the Bill

THD America offers a close parallel. In September 2024, the company and its corporate parent agreed to pay $700,000, a larger settlement than Paradigm’s, to resolve allegations involving coding advice for the Slide One Kit, a hemorrhoid removal system.

The government alleged that physicians were required to use a temporary procedure code and that reimbursement was often denied. THD allegedly encouraged surgeons to add another code or use substitute codes to obtain payment from Medicare and Medicaid. A former employee brought that whistleblower case, too.

The common thread is the manufacturer’s alleged instruction reaching the provider’s bill. A medical device sale gives the manufacturer a commercial interest in reimbursement, while the physician or hospital supplies the claim. The insider who knows how those two sides communicated can explain where the billing story came from.

You Know What the Practice Was Told

If you worked in medical device sales, training or reimbursement and know how a questionable billing recommendation reached a provider, bring that account to our whistleblower experts. We build the case with you and bring in medical device fraud whistleblower lawyers who understand how manufacturer instructions can cause provider claims. We stay beside you throughout the process, working to turn what you know into your strongest medical device whistleblower case.

WHISTLEBLOWER JUSTICE NETWORK CAN HELP YOU
Make a difference.
Whistleblower Justice NetworkReport Fraud
100% CONFIDENTIALFREE CONSULTATION24 / 7 / 365